Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells

Endocrine

Volumn 47, Issue 3, 2014, Pages 943-951

  Gagliano, Teresa ^a   Gentilin, Erica ^a   Benfini, Katiuscia ^a   Di Pasquale, Carmelina ^a   Tassinari, Martina ^a   Falletta, Simona ^a   Feo, Carlo ^a   Tagliati, Federico ^a   Uberti, Ettore degli ^a   Zatelli, Maria Chiara ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Adrenocortical cancer; Chemoresistance; Mitotane; P gp

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; CASPASE 3; CASPASE 7; DOXORUBICIN; MITOTANE; MULTIDRUG RESISTANCE PROTEIN; VERAPAMIL; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADRENOCORTICAL CARCINOMA CELL LINE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER COMBINATION CHEMOTHERAPY; CELL LEVEL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CELL LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; LOW DRUG DOSE; MONOTHERAPY; MTT ASSAY; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTAGONISTS AND INHIBITORS; CELL DEATH; CELL SURVIVAL; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MITOTANE; P-GLYCOPROTEIN;

EID: 84911959815     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0374-z     Document Type: Article

References (41)

1. M. Terzolo, F. Daffara, A. Ardito, B. Zaggia, V. Basile, L. Ferrari, A. Berruti, Management of adrenal cancer: a 2013 update. J. Endocrinol. Invest. 37, 207–217 (2014)
2. M. Fassnacht, M. Kroiss, B. Allolio, Update in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 98, 4551–4564 (2013)
3. M. Terzolo, A. Angeli, M. Fassnacht, F. Daffara, L. Tauchmanova, P.A. Conton, R. Rossetto, L. Buci, P. Sperone, E. Grossrubatscher, G. Reimondo, E. Bollito, M. Papotti, W. Saeger, S. Hahner, A.C. Koschker, E. Arvat, B. Ambrosi, P. Loli, G. Lombardi, M. Mannelli, P. Bruzzi, F. Mantero, B. Allolio, L. Dogliotti, A. Berruti, Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 356, 2372–2380 (2007)
4. S.D. Flynn, J.R. Murren, W.M. Kirby, J. Honig, L. Kann, B.K. Kinder, P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery. 112, 981–986 (1992)
5. F.J. Sharom, ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 9, 105–127 (2008)
6. L. Bao, A. Haque, K. Jackson, S. Hazari, K. Moroz, R. Jetly, S. Dash, Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am. J. Pathol. 178, 838–852 (2011)
7. T. Stankovic, E. Marston, Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia. Srp. Arh. Celok. Lek. 136, 187–192 (2008)
8. M.C. Zatelli, A. Luchin, D. Piccin, F. Tagliati, A. Bottoni, C. Vignali, M. Bondanelli, E.C. Degli Uberti, Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J. Clin. Endocrinol. Metab. 90, 5754–5760 (2005)
9. M.C. Zatelli, A. Luchin, F. Tagliati, S. Leoni, D. Piccin, M. Bondanelli, R. Rossi, E.C. Degli Uberti, Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr. Relat. Cancer 14, 1029–1038 (2007)
10. M.C. Zatelli, D. Molè, F. Tagliati, M. Minoia, Ambrosio, E. Degli Uberti, Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-kappaB. Cell. Oncol. 31, 457–465 (2009)
11. S.E. Bates, C.Y. Shieh, L.A. Mickley, H.L. Dichek, A. Gazdar, D.L. Loriaux, A.T. Fojo, Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J. Clin. Endocrinol. Metab. 73, 18–29 (1991)
12. M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak, A. Berruti, S. Welin, C. Schade-Brittinger, A. Lacroix, B. Jarzab, H. Sorbye, D.J. Torpy, V. Stepan, D.E. Schteingart, W. Arlt, M. Kroiss, S. Leboulleux, P. Sperone, A. Sundin, I. Hermsen, S. Hahner, H.S. Willenberg, A. Tabarin, M. Quinkler, C. de la Fouchardière, M. Schlumberger, F. Mantero, D. Weismann, F. Beuschlein, H. Gelderblom, H. Wilmink, M. Sender, M. Edgerly, W. Kenn, T. Fojo, H.H. Müller, B. Skogseid, FIRM-ACT Study Group: combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189–2197 (2012)
13. I. Veytsman, L. Nieman, T. Fojo, Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J. Clin. Oncol. 27, 4619–4629 (2009)
14. M.C. Zatelli, E. Gentilin, F. Daffara, F. Tagliati, G. Reimondo, G. Carandina, Ambrosio, M. Terzolo, E.C. Degli Uberti, Therapeutic concentrations of mitotane (o,p’-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 151, 2453–2461 (2010)
15. E. Gentilin, F. Tagliati, M. Terzolo, M. Zoli, M. Lapparelli, M. Minoia, M.R. Ambrosio, E.C. degli Uberti, M.C. Zatelli, Mitotane reduces human and mouse ACTH-secreting pituitary cells viability and function. J. Endocrinol. 218, 275–285 (2013)
16. E. Gentilin, D. Molè, T. Gagliano, M. Minoia, M.R. Ambrosio, E.C. Degli Uberti, M.C. Zatelli, Inhibitory effects of mitotane on viability and secretory activity in mouse gonadotroph cell lines. Reprod. Toxicol. 45, 71–76 (2014)
17. M.C. Zatelli, R. Rossi, E.C. Degli Uberti, Androgen influences Transforming Growth Factor Beta1 (TGF b1) gene expression in human adrenocortical cells. J. Clin. Endocrinol. Metab. 85, 847–852 (2000)
18. R. Rossi, M.C. Zatelli, A. Valentini, P. Cavazzini, F. Fallo, L. del Senno, E.C. degli Uberti, Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells. J. Endocrinol. 159, 373–380 (1998)
19. M.C. Zatelli, D. Piccin, F. Tagliati, A. Bottoni, A. Luchin, C. Vignali, A. Margutti, M. Bondanelli, G.C. Pansini, Pelizzo, M.D. Culler, E.C. Degli Uberti, Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J. Clin. Endocrinol. Metab. 91, 2218–2224 (2006)
20. M.C. Zatelli, F. Tagliati, D. Piccin, J.E. Taylor, M.D. Culler, M. Bondanelli, E.C. Degli Uberti, Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem. Biophys. Res. Commun. 29, 828–834 (2002)
21. T. Gagliano, M. Bellio, E. Gentilin, D. Molè, F. Tagliati, M. Schiavon, N.G. Cavallesco, L.G. Andriolo, M.R. Ambrosio, F. Rea, E. degli Uberti, M.C. Zatelli, mTOR, p70S6 K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3 K/mTOR inhibitors in human bronchial carcinoids. Endocr. Relat. Cancer 20, 463–475 (2013)
22. F. Tagliati, M.C. Zatelli, A. Bottoni, D. Piccin, A. Luchin, M.D. Culler, E.C. degli Uberti, Role of complex Cyclin D1/Cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro. Endocrinology 147, 3530–3538 (2006)
23. K. Fujimoto, G. Fujii, M. Mutoh, M. Yasunaga, H. Tanaka, M. Wada, Suppression of intestinal polyp development in Apc(Min/+) mice through inhibition of P-glycoprotein using verapamil. Eur. J. Cancer Prev. 22, 8–10 (2013)
24. R.A. Decker, P. Elson, T.F. Hogan, D.L. Citrin, D.W. Westring, T.K. Banerjee, K.W. Gilchrist, J. Horton, Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery. 110, 1006–1013 (1991)
25. C. Hantel, S. Jung, T. Mussack, M. Reincke, F. Beuschlein, Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model. Endocr. Relat. Cancer 21, 383–394 (2014)
26. R. Villa, L. Orlandi, A. Berruti, L. Dogliotti, N. Zaffaroni, Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int. J. Oncol. 14, 133–138 (1999)
27. G. Poli, D. Guasti, E. Rapizzi, R. Fucci, L. Canu, A. Bandini, N. Cini, D. Bani, M. Mannelli, M. Luconi, Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr. Relat. Cancer 20, 537–550 (2013)
28. P.M. van Koetsveld, G. Vitale, R.A. Feelders, M. Waaijers, D.M. Sprij-Mooij, R.R. de Krijger, E.J. Speel, J. Hofland, S.W. Lamberts, W.W. de Herder, L.J. Hofland, Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Endocr. Relat. Cancer 20, 443–454 (2013)
29. M.C. Zatelli, R. Rossi, L. del Senno, E.C. Degli Uberti, Role of transforming growth factor beta 1 (TGF beta 1) in mediating androgen-induced growth inhibition in human adrenal cortex in vitro. Steroids 63, 243–245 (1998)
30. M.C. Zatelli, M. Minoia, C. Martini, F. Tagliati, Ambrosio, M. Schiavon, M. Buratto, F. Calabrese, F. Calabrese, E. Gentilin, G. Cavallesco, L. Berdondini, F. Rea, E.C. Degli Uberti, Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr. Relat. Cancer 28, 719–729 (2010)
31. M.C. Zatelli, M. Minoia, C. Filieri, F. Tagliati, M. Buratto, Ambrosio, M. Lapparelli, M. Scanarini, E.C. Degli Uberti, Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 95, 968–976 (2010)
32. D.R. Barpe, D.D. Rosa, P.E. Froehlich, Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur. J. Pharm. Sci. 41, 458–463 (2010)
33. E. Bello-Reuss, S. Ernest, O.B. Holland, M.R. Hellmich, Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am. J. Physiol. Cell Physiol. 278, 1256–1265 (2000)
34. K. Ueda, D.P. Clark, C.J. Chen, I.B. Roninson, M.M. Gottesman, I. Pastan, The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J. Biol. Chem. 262, 505–508 (1987)
35. M. Dean, The Human ATP-Binding Cassette (ABC) Transporter Superfamily (National Library of Medicine, US, 2002)
36. H.R. Haak, A.P. van Seters, A.J. Moolenaar, G.J. Fleuren, Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur. J. Cancer 29A, 1036–1038 (1993)
37. S.D. Flynn, J.R. Murren, W.M. Kirby, J. Honig, L. Kann, B.K. Kinder, P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery. 112, 981–986 (1992)
38. J. Abraham, S. Bakke, A. Rutt, B. Meadows, M. Merino, R. Alexander, D. Schrump, D. Bartlett, P. Choyke, R. Robey, E. Hung, S.M. Steinberg, S. Bates, T. Fojo, A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94, 2333–2343 (2002)
39. F. Daffara, S. De Francia, G. Reimondo, B. Zaggia, M. Arosio, F. Porpiglia, M. Volante, A. Termine, F. Di Carlo, L. Dogliotti, A. Angeli, A. Berruti, M. Terzolo, Prospective evaluation of mitotane toxicity in adrenalcortical cancer patients treated adjuvantly. Endocr. Relat. Cancer 15, 1043–1053 (2008)
40. M. Lotrionte, G. Biondi-Zoccai, A. Abbate, G. Lanzetta, F. D’Ascenzo, V. Malavasi, M. Peruzzi, G. Frati, G. Palazzoni, Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am. J. Cardiol. 112, 1980–1984 (2013)
41. D. Ferone, C. Pivonello, G. Vitale, M.C. Zatelli, A. Colao, R. Pivonello, Molecular basis of pharmacological therapy in Cushing’s disease. Endocrine 46, 181–198 (2014)